Compare · CBLL vs NRXS
CBLL vs NRXS
Side-by-side comparison of CeriBell Inc. (CBLL) and Neuraxis Inc. (NRXS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CBLL and NRXS operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- CBLL is the larger of the two at $1.00B, about 15.7x NRXS ($63.9M).
- CBLL has been more active in the news (11 items in the past 4 weeks vs 5 for NRXS).
- CBLL has more recent analyst coverage (8 ratings vs 0 for NRXS).
- Company
- CeriBell Inc.
- Neuraxis Inc.
- Price
- -
- -
- Market cap
- $1.00B
- $63.9M
- 1M return
- -4.79%
- -
- 1Y return
- +89.44%
- -
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- AMEX
- IPO
- 2024
- 2023
- News (4w)
- 11
- 5
- Recent ratings
- 8
- 0
Latest CBLL
- Director Josef Parvizi sold $650,500 worth of shares (25,000 units at $26.02) as part of a pre-agreed trading plan (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by CeriBell Inc.
- Director Burke William W exercised 18,000 shares at a strike of $4.70 and sold $479,480 worth of shares (18,000 units at $26.64) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by CeriBell Inc.
- Director Taylor Joseph Michael sold $277,644 worth of shares (10,200 units at $27.22), decreasing direct ownership by 21% to 38,278 units (SEC Form 4)
- Chief Technology Officer Woo Raymond exercised 4,887 shares at a strike of $3.65 and sold $131,754 worth of shares (4,887 units at $26.96) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 10-Q filed by CeriBell Inc.
- CeriBell Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Ceribell Reports Third Quarter 2026 Financial Results
- Ceribell Expands Its Point-of-Care Brain Monitoring Platform with Commercial Launch of Delirium Monitoring Solution
Latest NRXS
- Amendment: SEC Form SCHEDULE 13D/A filed by Neuraxis Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Neuraxis Inc.
- NeurAxis Reports Record Third Quarter 2026 Financial Results Driven by 150% Year Over Year Revenue Growth
- SEC Form 10-Q filed by Neuraxis Inc.
- NeurAxis to Host Third Quarter 2026 Results and Business Update Call on Monday, November 9, 2026
- NeurAxis Announces Medical Policy Coverage Milestone, Expanding Access to 26 Million Additional Covered Lives
- SEC Form 8-K filed by Neuraxis Inc.
- Chief Executive Officer Carrico Brian Allen bought $1,297 worth of shares (268 units at $4.84) (SEC Form 4)
- CRO, CCO, CPO Carrico Thomas Joeseph bought $1,588 worth of shares (328 units at $4.84) (SEC Form 4)
- Chief Financial Officer Henrichs Timothy Robert bought $9,375 worth of shares (1,937 units at $4.84) (SEC Form 4)